JSR Life Sciences to buy cell line developer Selexis

Founded in 2001, Selexis is a scientific pioneer in mammalian (suspension-adapted CHO-K1) cell line generation that helps partners to develop innovative therapies.

Its cell line expression technologies can be used in the discovery and development of therapeutic proteins.

Selexis provides SUREtechnology platform, which is said to facilitate the stable and cost-effective generation of cell lines producing virtually any recombinant protein.

According to Selexis, It has generated 80 research cell banks, which are being used for commercial manufacturing in clinical trials and two marketed products in oncology and inflammation.

The company secured 154 patents, which cover innovations in genetic elements, procedures/transfection, cell line engineering, and devices related to cell line development and protein expression.  

Once the deal concludes, JSR will include Selexis within KBI Biopharma’s operations, which was acquired in 2015. The combination will help to create advanced Gene to GMP service offering in the biopharmaceutical industry.

JSR’s life sciences division president Eric Johnson said: “Selexis has the best-in-class cell line development technology and offers the ability to solve some of the most difficult expression challenges in biologics development.

Selexis CEO Dr Igor Fisch said: “Combining KBI’s robust analytical, process development, and reliable high-quality manufacturing capabilities with our Selexis SUREtechnology Platform, puts us in a position to offer current and future partners the ability to take their R&D programs from transfection to investigational new drug (IND) application in less than nine months.”

With manufacturing facilities, sales offices and R&D labs in  throughout North America, Europe and AsiaPacific, JSR Life Sciences offers specialized materials and products to the biotech industry.

Image: JSR Life Sciences to acquire life sciences firm Selexis. Photo: courtesy of adamr / FreeDigitalPhotos.net.